ÿþ <html> <body> <fieldset> <legend> SAMs Florida Chapter AAPM: THERAPY SAM (Mammosite) </legend> <br> <b>*PLEASE FILL OUT ALL FIELDS*</b> <form action="MAILTO:amish.shah@orlandohealth.com;thomas.wagner@orlandohealth.com" method="post" enctype="text/plain"> <input type="hidden" name="Which SAM?" value="Mammosite"> <br> First name: <input type="text" name="firstname"> <br> Last name: <input type=" text" name="lastname"> Suffix: <input type=" text" name="suffix" size="14"> <br> Company: <input type=" text" name="company" size="46"> <br> Title(s): <input type=" text" name="title" size="49"> <br> Mailing Address: <input type=" text" name="address" size="40"> <br> Mailing Address: <input type=" text" name="address" size="40"> <br> City: <input type=" text" name="city" size="20"> State: <input type=" text" name="state" size="10"> Zip: <input type=" text" name="zip" size="10"> <br> Phone Number: <input type=" text" name="phone" size="44"> <br> Email Address: <input type=" text" name="email" size="45"> <br> <br> <b>Please indicate ONE best answer for each question (if you make a mistake, click "RESET" at the bottom of this page):</b> <br> <br> <b>Q1. Which of the following events would NOT constitute a mammosite HDR misadministration?</b> <br> <INPUT TYPE=RADIO NAME="(1)" value="a1"> (A) Mammosite treatment intended for Ms. Smith delivered to mammosite patient Ms. Jones <br> <INPUT TYPE=RADIO NAME="(1)" value="b1"> (B) Mammosite treatment intended to be given at a treatment distance of 1282mm but later determined to have been given at 1283mm <br> <INPUT TYPE=RADIO NAME="(1)" value="c1"> (C) Mammosite treatment given with leaking Ir-192 HDR source <br> <INPUT TYPE=RADIO NAME="(1)" value="d1"> (D) HDR dose delivered was 21% over the prescribed treatment dose <br> <INPUT TYPE=RADIO NAME="(1)" value="e1"> (E) Mammosite treatment prescribed 3400 cGy/10 b.i.d. fractions was accidentally delivered with a Co-60 source instead of the prescribed Ir-192 (in an HDR/PDR unit equipped with multiple HDR sources) <br> <br> <b>Q2. What is the maximum amount of non-conforming volume (selected from the list below) which is still acceptable for Mammosite HDR treatment?</b> <br> <INPUT TYPE=RADIO NAME="(2)" value="a2"> (A) 0.9% of the PTV volume <br> <INPUT TYPE=RADIO NAME="(2)" value="b2"> (B) 1.1% of the PTV volume <br> <INPUT TYPE=RADIO NAME="(2)" value="c2"> (C) 9.0% of the PTV volume <br> <INPUT TYPE=RADIO NAME="(2)" value="d2"> (D) 11% of the PTV volume <br> <INPUT TYPE=RADIO NAME="(2)" value="e2"> (E) 15% of the PTV volume <br> <br> <b>Q3. Which of the following situations would result in the greatest amount of attenuation of the HDR dose at the prescribed 1cm distance from the balloon surface?</b> <br> <INPUT TYPE=RADIO NAME="(3)" value="a3"> (A) A 5% concentration of iodine contrast media in a 4.2cm diameter balloon. <br> <INPUT TYPE=RADIO NAME="(3)" value="b3"> (B) A 5% concentration of iodine contrast media in a 6cm diameter balloon. <br> <INPUT TYPE=RADIO NAME="(3)" value="c3"> (C) A 15% concentration of iodine contrast media in a 4.2cm diameter balloon. <br> <INPUT TYPE=RADIO NAME="(3)" value="d3"> (D) A 15% concentration of iodine contrast media in a 6cm diameter balloon. <br> <INPUT TYPE=RADIO NAME="(3)" value="e3"> (E) A 25% concentration of iodine contrast media in a 4.2cm diameter balloon. <br> <INPUT TYPE=RADIO NAME="(3)" value="f3"> (F) A 25% concentration of iodine contrast media in a 6cm diameter balloon. <br> <br> <b>Q4. What is the TG-43 dose rate constant (›) for an Ir-192 HDR source?</b> <br> <INPUT TYPE=RADIO NAME="(4)" value="a4"> (A) 0.74 cGy-hr-1-U-1 <br> <INPUT TYPE=RADIO NAME="(4)" value="b4"> (B) 0.88 cGy-hr-1-U-1 <br> <INPUT TYPE=RADIO NAME="(4)" value="c4"> (C) 0.93 cGy-hr-1-U-1 <br> <INPUT TYPE=RADIO NAME="(4)" value="d4"> (D) 0.98 cGy-hr-1-U-1 <br> <INPUT TYPE=RADIO NAME="(4)" value="e4"> (E) 1.12 cGy-hr-1-U-1 <br> <br> <b>Q5. Which of the statements below is not an argument in favor of Mammosite accelerated partial breast irradiation?</b> <br> <INPUT TYPE=RADIO NAME="(5)" value="a5"> (A) External beam radiation to the entire breast is postulated to reduce the local recurrence of breast cancer by 20-30% (compared to lumpectomy alone), as well as eliminating cancer in remote areas of the breast. <br> <INPUT TYPE=RADIO NAME="(5)" value="b5"> (B) Between 65% to 100% of recurrences develop in the same quadrant of the breast as the initial tumor. <br> <INPUT TYPE=RADIO NAME="(5)" value="c5"> (C) At worst, only 3.8% of lumpectomy patients develop a recurrence in a remote location in the breast, relative to the lumpectomy site. <br> <INPUT TYPE=RADIO NAME="(5)" value="d5"> (D) Breast conserving therapy trials in which post-operative radiation was omitted demonstrate that recurrences were much more common at or near the surgical site than remote in-breast recurrences. <br> <INPUT TYPE=RADIO NAME="(5)" value="e5"> (E) Studies indicate that the major benefit of post-surgical radiation is derived from the radiation directed at the tissue immediately surrounding the lumpectomy site. <br> <br> <b>If you have not already paid via Paypal, please acknowledge you must first make payment to receive any SAMs credit</b> <br> <INPUT TYPE=RADIO NAME="Paypal" value="Paypal"> Okay, I will now proceed to PayPal. <br> <INPUT TYPE=RADIO NAME="Paypal" value="Attendee"> N/A, I have already paid! <br> <br> <br> <b>IMPORTANT note: when you press "Submit", please allow email YOUR server to send an email!</b> <br> <br> <name="input" action="html_form_action.asp" method="get"> Comments: <input type="text" name="user comments " size="45"> <input type="submit" value="Submit"> <input type="Reset" value="Reset"> </form> </body> </html>